Sacubitril/valsartan in COVID-19 patients: the need for trials-Reference-Cited by-同舟云学术

Sacubitril/valsartan in COVID-19 patients: the need for trials

Published:2020-05-05 Issue:4 Volume:6 Page:253-254
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Acanfora Domenico¹,Ciccone Marco Matteo²,Scicchitano Pietro²³^ORCID,Acanfora Chiara¹⁴,Casucci Gerardo¹

Affiliation:

1. Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme, BN, Italy

2. Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, University of Bari, School of Medicine, Bari, Italy

3. Cardiology Unit, Hospital ‘F. Perinei’ Altamura, Bari, Italy

4. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvaa044/33166801/pvaa044.pdf

Reference10 articles.

1. Response to: Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan;Petramala;Eur Heart J Cardiovasc Pharmacother,2020

2. Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients;Acanfora;Eur Heart J Cardiovasc Pharmacother,2020

3. Renin–angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension;Iaccarino;High Blood Press Cardiovasc Prev,2020

4. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19;Zhang;Circ Res,2020

5. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect;Sommerstein;J Am Heart Assoc,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PERINDOPRIL AND LOSARTAN ATTENUATE PRO-COAGULATION FACTORS IN HUMAN ADIPOCYTES EXPOSED TO SARS-COV-2 SPIKE PROTEIN;J PHYSIOL PHARMACOL;2023

2. An overview on the treatments and prevention against COVID-19;Virology Journal;2023-02-08

3. Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?;OMICS: A Journal of Integrative Biology;2021-07-01

4. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients;Wiener klinische Wochenschrift;2021-04-20

5. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID‐19?;Physiological Reports;2021-03